全球特殊医药品的联盟条件与契约 (2019～2024年)

本报告提供了有关公司为何以及在什么条件下签订专业製药合作协议的详细资讯和分析。这些协议往往是多方面的，从联合研发开始，一直到成果的商业化。

本报告提供了自 2019 年以来生命科学领域宣布的 1,066 项特种製药协议的详细资讯。

本报告对特种药品领域的合约趋势、主要公司、主要合约金额和合约财务进行了全面回顾，并研究了每家公司如何、为何以及在什么条件下签订特种药品合作协议，您可以了解什么。

本报告从财务角度评估了特种药品交易的期限和价值，并提供了交易总额、预付款、里程碑和特许权使用费率等信息，以帮助读者了解交易的财务价值。比较。

本报告的中间部分研究了专业製药联盟的主要交易者。报告了特种药品领域主要交易的交易价值和最活跃的交易撮合者，让读者了解哪些公司在这个充满活力的交易市场中取得了成功。

对于特殊药品的实际交易，我们提供交易方揭露的线上交易记录，按公司名称（A-Z）、开发阶段、交易类型、特定治疗标靶和技术类型列于报告末尾。 。报告中的每个交易记录都透过网路连结连结到交易的线上版本。

此外，如果有的话，我们会记录公司及其附属公司向美国证券交易委员会提交的合约文件。虽然许多公司希望了解其付款条件的详细信息，但在付款方式方面，细节才是王道。

本报告还包括一些图表，显示 2019 年以来专业製药联盟和交易的趋势和活动。

总之，我们为未来的交易者提供了有关专业药品研发和商业化合作所需的一切资讯。

主要优点

该报告为读者提供了以下主要好处：

• 有关特种药品合约趋势的详细资讯（自 2019 年起）
• 取得交易金额、预付款、里程碑和版税率数据
• 与主要生物製药公司签署的特种药品实际协议：查看详细信息
• 确定特种药品领域最活跃的交易撮合者（2019 年及以后）
• 公司过去同意的主要合约条件的说明
• 进行尽职调查：评估向合作伙伴公司提出的合约条款的适当性

调查范围

• 本报告旨在让读者深入了解和了解全球领先的特种药品公司所进行的交易的趋势和结构。

特种药物的合作条件与合约细节：

• 生医产业专科药品贸易趋势（2019年起）
• 取得交易金额、预付款、里程碑和版税率数据
• 取得特种药物的合约文件
• 特种药品主要总交易额和k需求（2019年以来）
• 专业药品领域最活跃的交易撮合者（2019 年起）

此报告列出了可用合约的以下资讯：

• 公司名称（A-Z）
• 总交易金额
• 合约签订时的开发阶段
• 合约组成部分的类型
• 具体治疗标靶
• 技术类型
• 每笔交易的标题都透过网路连结连结到交易记录的线上版本以及合约文件（如果有），从而可以轻鬆按需存取每份合约文件。

透过分析实际合同，可以评估：

• 授予或选择的具体权利是什么？
• 合约实际上赋予了合作伙伴公司什么？
• 授予哪些类型的专有权？
• 合约的付款结构是怎样的？
• 如何审核销售和付款？
• 条款和条件是什么？
• 合约的主要条款是如何定义的？
• 智慧财产权的处理和所有权如何？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和发布？
• 如何解决争议？
• 什么情况下可以取消合约？
• 如果所有者发生变化会怎样？
• 已就何种类型的分授权或分包条款达成协议？
• 公司主张哪些样板条款？
• 根据合作伙伴关係或交易的类型，哪些样板条款看起来有所不同？
• 公司对契约法主张哪一个管辖权？

目录

摘要整理

第1章 简介

第2章 特殊医药品的交易趋势

• 简介
• 特殊医药品的长期性的联盟趋势
• 在特殊医药品中最活跃的交易商
• 特殊医药品的联盟趋势:各交易类型
• 特殊医药品的联盟趋势:各治疗领域
• 特殊医药品的联盟趋势:各技术种类
• 特殊医药品的联盟条件
  • 特殊医药品的联盟的交易总额
  • 特殊医药品的交易的预付款金
  • 特殊医药品的交易的里程金
  • 特殊医药品的特许权率

第3章 特殊医药品的主要交易

• 简介
• 特殊医药品的主要交易:交易额

第4章 特殊医药品的最活跃的交易商

• 简介
• 特殊医药品的最活跃的交易商
• 特殊医药品的最活跃的联盟企业:简介

第5章 特殊医药品的契约交易一览

• 简介
• 特殊医药品的契约交易一览

第6章 特殊医药品的交易趋势:各技术种类

附录

Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024 report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals.

This report provides details of 1,066 specialty pharmaceutical agreements announced in the life sciences since 2019.

The report takes the reader through a comprehensive review specialty pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering specialty pharmaceutical partnering deals.

The report presents financial deal term values for specialty pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the specialty pharmaceutical partnering field; both the leading deal values and most active specialty pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

Online deal records of actual specialty pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via hyperlink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of specialty pharmaceutical dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in specialty pharmaceutical dealmaking since 2019, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading specialty pharmaceutical deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in specialty pharmaceutical dealmaking with a brief summary followed by a comprehensive listing of specialty pharmaceutical deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of specialty pharmaceutical partnering deals signed and announced since January 2019, where a contract document is available in the public domain. Each deal title links via hyperlink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of specialty pharmaceutical partnering deals signed and announced since January 2019. The chapter is organized by specific technology type. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by specialty pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in specialty pharmaceutical partnering and dealmaking since 2019.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of specialty pharmaceutical technologies and products.

Key benefits

Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024 provides the reader with the following key benefits:

• In-depth understanding of specialty pharmaceutical deal trends since 2019
• Access to headline, upfront, milestone and royalty data
• Detailed access to actual specialty pharmaceutical contracts entered into by leading biopharma companies
• Identify most active specialty pharmaceutical dealmakers since 2019
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

• Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024 is intended to provide the reader with an in-depth understanding and access to specialty pharmaceutical trends and structure of deals entered into by leading companies worldwide.

Specialty Pharmaceutical Partnering Terms and Agreements includes:

• Trends in specialty pharmaceutical dealmaking in the biopharma industry since 2019
• Access to headline, upfront, milestone and royalty data
• Access to specialty pharmaceutical contract documents
• Leading specialty pharmaceutical deals by value since 2019
• Most active specialty pharmaceutical dealmakers since 2019

In Global Specialty Pharmaceutical Partnering Terms and Agreements, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
• Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in specialty pharmaceutical dealmaking

• 2.1. Introduction
• 2.2. Specialty pharmaceutical partnering over the years
• 2.3. Most active specialty pharmaceutical dealmakers
• 2.4. Specialty pharmaceutical partnering by deal type
• 2.5. Specialty pharmaceutical partnering by therapy area
• 2.6. Specialty pharmaceutical partnering by technology type
• 2.7. Deal terms for specialty pharmaceutical partnering
  • 2.7.1 Specialty pharmaceutical partnering headline values
  • 2.7.2 Specialty pharmaceutical deal upfront payments
  • 2.7.3 Specialty pharmaceutical deal milestone payments
  • 2.7.4 Specialty pharmaceutical royalty rates

Chapter 3 - Leading specialty pharmaceutical deals

• 3.1. Introduction
• 3.2. Top specialty pharmaceutical deals by value

Chapter 4 - Most active specialty pharmaceutical dealmakers

• 4.1. Introduction
• 4.2. Most active specialty pharmaceutical dealmakers
• 4.3. Most active specialty pharmaceutical partnering company profiles

Chapter 5 - Specialty pharmaceutical contracts dealmaking directory

• 5.1. Introduction
• 5.2. Specialty pharmaceutical contracts dealmaking directory

Chapter 6 - Specialty pharmaceutical dealmaking by technology type

Appendices

• Appendix 1 - Specialty pharmaceutical deals by company A-Z
• Appendix 2 - Specialty pharmaceutical deals by stage of development
• Appendix 3 - Specialty pharmaceutical deals by deal type
• Appendix 4 - Specialty pharmaceutical deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Specialty pharmaceutical partnering since 2019
• Figure 2: Active specialty pharmaceutical dealmaking activity 2019-2024
• Figure 3: Specialty pharmaceutical partnering by deal type since 2019
• Figure 4: Specialty pharmaceutical partnering by disease type since 2019
• Figure 5: Specialty pharmaceutical partnering by technology type since 2019
• Figure 6: Specialty pharmaceutical deals with a headline value
• Figure 7: Specialty pharmaceutical deals with an upfront value
• Figure 8: Specialty pharmaceutical deals with a milestone value
• Figure 9: Specialty pharmaceutical deals with a royalty rate value
• Figure 10: Top specialty pharmaceutical deals by value since 2019
• Figure 11: Most active specialty pharmaceutical dealmakers 2019-2024